New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
- 1 June 2012
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 38 (4) , 303-310
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?Journal of Clinical Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Reproductive history and risk of three breast cancer subtypes defined by three biomarkersCancer Causes & Control, 2010
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Design and analysis issues in genome-wide somatic mutation studies of cancerGenomics, 2009
- IGF-1 Receptor Inhibitors in Clinical Trials—Early LessonsJournal of Mammary Gland Biology and Neoplasia, 2008
- Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancerBreast Cancer Research and Treatment, 2008
- Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 2007
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004